Zoraxel Could Knock Viagra Off Top Spot
Written by Stuart Stevens | Thursday, 05 June 2008 | There are 0 comments
The big news in the world of erectile dysfunction medication is that Rexahn Pharmaceuticals has announced the beginning of phase two clinical trials for an exciting new medication called Zoraxel. Zoraxel has been developed to be an oral pill to be taken by men just before sexual activity in the same way as Viagra, Cialis and Levitra are.

Dr. Chang Ahn who is the Chairman and the Chief Executive Officer of Rexahn Pharmaceuticals said that it is hoped that Zoraxel will prove to be an extremely effective erectile dysfunction remedy which will be tolerated by all men. The Phase II trial for Zoraxel is to be a placebo controlled, double blind study which should be completed before the beginning of 2009.
Unlike the other three erectile dysfunction drugs (Viagra, Cialis and Levitra) on the market Zoraxel is not a PDE-5 inhibitor so that people who suffer from the side effects of using this type of medication will be potential patients for the Zoraxel impotence drug. Zoraxel works by acting on the part of the central nervous system which controls sexual function. In testing Zoraxel has been identified as significantly improving the three main functions of sexual intercourse. It was noted that men experienced heightened sexual arousal, stronger erections and improved sexual release.
If this is the case and it can be conclusively proved that Zoraxel has a significant effect on these three aspects of sexual intercourse it will be a revolutionary medication. The erectile dysfunction drugs Viagra, Cialis and Levitra work by increasing sexual function in men by giving them better erections but they do not have an effect on sexual desire and sexual release as it is claimed that Zoraxel does.
The market for erectile dysfunction medication is worth billions of pounds worldwide as Pfizer found out when it launched its impotence drug Viagra. If Rexahn Pharmaceuticals can show that Zoraxel is both efficient and safe it will be on to a worldwide best-selling drug.


